Joachim R Gruber, 57151 Windsor Ave, Bardstown, KY 40004

6403557, Jun 11, 2002

Nov 21, 1997

08/976315

John M. Greene - Gaithersburg MD
Joachim R. Gruber - Dallas TX
Craig A. Rosen - Laytonsville MD

Human Genome Sciences, Inc. - Rockville MD

A61K 3818

514 12, 530350, 530399, 514 2

The present invention relates to a novel FGF-13 protein which is a member of the fibroblast growth factor (FGF) family. In particular, isolated nucleic acid molecules are provided encoding the human FGF-13 protein. FGF-13 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of FGF-13 activity. Also provided are diagnostic methods for detecting FGF-13-related disorders and therapeutic methods for treating FGF-13-related disorders. Disclosed is a method of prolonging dopaminergic neuron survival.

6693077, Feb 17, 2004

Jun 30, 2000

09/610651

Steven M. Ruben - Brookeville MD
Pablo Jimenez - Chatham NJ
D. Roxanne Duan - Gaithersburg MD
Mark A. Rampy - Montgomery Village MD
Donna Mendrick - Mount Airy MD
Jun Zhang - San Diego CA
Jian NI - Germantown MD
Paul A. Moore - North Bethesda MD
Timothy A. Coleman - Gaithersburg MD
Joachim R. Gruber - Dallas TX
Patrick J. Dillon - Carlsbad CA
Reiner L. Gentz - Belo Horizonte-Mg, BR

Human Genome Sciences, Inc. - Rockville MD

A61K 3818

514 12, 514 2, 530399

This invention relates to newly identified polynucleotides, polypeptides encoded by such polynucleotides, the use of such polynucleotides and polypeptides, as well as the production of such polynucleotides and polypeptides. More particularly, the polypeptide of the present invention is a Keratinocyte Growth Factor, sometimes hereinafter referred to as âKGF-2â also formerly known as Fibroblast Growth Factor 12 (FGF-12). This invention further relates to the therapeutic use of KGF-2 to promote or accelerate wound healing. This invention also relates to novel mutant forms of KGF-2 that show enhanced activity, increased stability, higher yield or better solubility.

6903072, Jun 7, 2005

Jul 1, 1999

09/345373

Steven M. Ruben - Olney MD, US
Pablo Jimenez - Ellicott City MD, US
D. Roxanne Duan - Bethesda MD, US
Mark A. Rampy - Gaithersburg MD, US
Donna Mendrick - Mt. Airy MD, US
Jun Zhang - Bethesda MD, US
Jian Ni - Rockville MD, US
Paul A. Moore - Germantown MD, US
Timothy A. Coleman - Gaithersburg MD, US
Joachim R. Gruber - Chestnut Hill MA, US
Patrick J. Dillon - Carlsbad CA, US
Reiner L. Gentz - Rockville MD, US

Human Genome Sciences, Inc. - Rockville MD

A61K038/18
C07K014/50
C12N015/18
C12N001/21

514 12, 514 2, 530399, 530402, 435 694, 435 697, 435243

This invention relates to newly identified polynucleotides, polypeptides encoded by such polynucleotides, the use of such polynucleotides and polypeptides, as well as the production of such polynucleotides and polypeptides. More particularly, the polypeptide of the present invention is a Keratinocyte Growth Factor, sometimes hereinafter referred to as “KGF-2” also formerly known as Fibroblast Growth Factor 12 (FGF-12). This invention further relates to the therapeutic use of KGF-2 to promote or accelerate wound healing. This invention also relates to novel mutant forms of KGF-2 that show enhanced activity, increased stability, higher yield or better solubility.

6916786, Jul 12, 2005

Feb 15, 2002

10/075446

Steven M. Ruben - Olney MD, US
Pablo Jimenez - Ellicot City MD, US
D. Roxanne Duan - Bethesda MD, US
Mark A. Rampy - Montgomery Village MD, US
Donna Mendrick - Mount Airy MD, US
Jun Zhang - Bethesda MD, US
Jian Ni - Rockville MD, US
Paul A. Moore - Germantown MD, US
Timothy A. Coleman - Gaithersburg MD, US
Joachim R. Gruber - Dallas TX, US
Patrick J. Dillon - Carlsbad CA, US
Reiner L. Gentz - Rockville MD, US

Human Genome Sciences, Inc. - Rockville MD

A61K038/18
C07K014/50
C12N001/20
C12N005/10

514 12, 530399, 435 694, 435 697, 435243

This invention relates to newly identified polynucleotides, polypeptides encoded by such polynucleotides, the use of such polynucleotides and polypeptides, as well as the production of such polynucleotides and polypeptides. More particularly, the polypeptide of the present invention is a Keratinocyte Growth Factor, sometimes hereinafter referred to as “KGF-2” also formerly known as Fibroblast Growth Factor 12 (FGF-12). This invention further relates to the therapeutic use of KGF-2 to promote or accelerate wound healing. This invention also relates to novel mutant forms of KGF-2 that show enhanced activity, increased stability, higher yield or better solubility.

7208584, Apr 24, 2007

Apr 17, 2002

10/123481

John M. Greene - Gaithersburg MD, US
Joachim R. Gruber - Dallas TX, US
Craig A. Rosen - Laytonsville MD, US

Human Genome Sciences, Inc. - Rockville MD

C07K 16/22
C07K 14/50

53038824, 5303871, 5303873, 5303881, 5303891, 5303892, 530866

The present invention relates to a novel FGF-13 protein which is a member of the fibroblast growth factor (FGF) family. In particular, isolated nucleic acid molecules are provided encoding the human FGF-13 protein. FGF-13 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of FGF-13 activity. Also provided are diagnostic methods for detecting FGF-13-related disorders and therapeutic methods for treating FGF-13-related disorders. Disclosed is a method of prolonging dopaminergic neuron survival.

7232667, Jun 19, 2007

Dec 12, 2003

10/733311

Steven M. Ruben - Brookeville MD, US
Joachim R. Gruber - Dallas TX, US
D. Roxanne Duan - Gaithersburg MD, US
Mark A. Rampy - Montgomery Village MD, US
Donna Mendrick - Mount Airy MD, US
Jun Zhang - San Diego CA, US
Jian Ni - Germantown MD, US
Paul A. Moore - Germantown MD, US
Timothy A. Coleman - Gaithersburg MD, US
Patrick J. Dillon - Carlsbad CA, US
Reiner L. Gentz - Belo Horizonte-Mg, BR
Pablo Jimenez - Chatham NJ, US

Human Genome Sciences, Inc. - Rockville MD

C12N 1/21
C12N 5/10
C12N 15/12
C12N 15/63
C07K 14/50

435 694, 435 697, 435325, 435243, 4353201, 536 234, 536 2351, 530399

This invention relates to newly identified polynucleotides, polypeptides encoded by such polynucleotides, the use of such polynucleotides and polypeptides, as well as the production of such polynucleotides and polypeptides. More particularly, the polypeptide of the present invention is a Keratinocyte Growth Factor, sometimes hereinafter referred to as “KGF-2” also formerly known as Fibroblast Growth Factor 12 (FGF-12). This invention further relates to the therapeutic use of KGF-2 to promote or accelerate wound healing. This invention also relates to novel mutant forms of KGF-2 that show enhanced activity, increased stability, higher yield or better solubility.

2002016, Nov 7, 2002

Sep 12, 2001

09/949842

Jian Ni - Germantown MD, US
David Hilbert - Bethesda MD, US
Joseph Kenny - Damascus MD, US
Paul Moore - Germantown MD, US
Gil Choi - Rockville MD, US
Daniel Soppet - Centreville VA, US
Reinhard Ebner - Gaithersburg MD, US
Joachim Gruber - Dallas TX, US
Gregory Endress - Florence MA, US
Steven Ruben - Olney MD, US

C12N009/00
C07H021/04
C12P021/02
C12N005/06

435/069100, 435/183000, 435/320100, 435/325000, 536/023200

The present invention relates to novel human immune system-related polypeptides and isolated nucleic acids containing the coding regions of the genes encoding such polypeptides. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human immune system-related polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human immune system-related polypeptides.

2003013, Jul 17, 2003

Mar 18, 2002

10/098449

John Greene - Gaithersburg MD, US
Joachim Gruber - Dallas TX, US
Craig Rosen - Laytonsville MD, US

Human Genome Sciences, Inc. - Rockville MD

C12Q001/68
C07H021/04
C12P021/02
C12N005/06
C07K014/50

435/069400, 435/325000, 435/006000, 435/320100, 536/023500, 530/399000

Disclosed is a human Fibroblast growth factor-13 polypeptide and DNA(RNA) encoding such polypeptide. Also provided is a procedure for producing such polypeptide by recombinant techniques. Also disclosed are methods for utilizing such polypeptide for promoting wound healing for example as a result of burns and ulcers, to prevent neuronal damage associated with stroke and due to neuronal disorders and promote neuronal growth, and to prevent skin aging and hair loss, to stimulate angiogenesis, mesodermal induction in early embryos and limb regeneration. Antagonists against such polypeptides and their use as a therapeutic to prevent abnormal cellular proliferation, hyper-vascular diseases and epithelial lens cell proliferation are also disclosed. Diagnostic methods for detecting mutations in the coding sequence and alterations in the concentration of the polypeptides in a sample derived from a host are also disclosed.